YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Although antitubulin drugs are used widely to treat human cancer, many patients display intrinsic or acquired drug resistance that imposes major obstacles to successful therapy. Mounting evidence argues that cancer cell apoptosis triggered by antitubulin drugs relies upon activation of the cell-cycle kinase Cdk1; however, mechanistic connections of this event to apoptosis remain obscure. In this study, we identified the antiapoptotic protein YAP, a core component of the Hippo signaling pathway implicated in tumorigenesis, as a critical linker coupling Cdk1 activation to apoptosis in the antitubulin drug response. Antitubulin drugs activated Cdk1, which directly phosphorylated YAP on five sites independent of the Hippo pathway. Mutations in these phosphorylation sites on YAP relieved its ability to block antitubulin drug-induced apoptosis, further suggesting that YAP was inactivated by Cdk1 phosphorylation. Notably, we found that YAP was not phosphorylated and inactivated after antitubulin drug treatment in taxol-resistant cancer cells. Our findings suggest YAP and its phosphorylation status as candidate prognostic markers in predicting antitubulin drug response in patients. Cancer Res; 74(16); 4493–503. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979 · cited 5×
“We and others have recently provided initial evidence that the core components of the Hippo pathway, LATS1/2, YAP, and TAZ, may be involved in the response of cancer cells to chemotherapeutic drugs such as taxol (14, 24– 26).”
BackgroundInfluentialZhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 1×
“Because LATS1/2 can phosphorylate YAP at five sites (15, 18), it is possible that LATS1may phosphorylate YAP on other sites rather than S127.”
BackgroundTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418 · cited 1×
“Most interestingly, three (S138, S289, and S367) out of five Cdk1 phosphorylation sites in YAP identified in our studies have already been identified previously in amass spectrometry mapping of YAP phosphorylation sites under physiologic conditions (31).”
BackgroundThe Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381
The Hippo pathway: regulators and regulations.
Yu, F.-X., & Guan, K.-L. (2013) · Genes & Development · doi:10.1101/gad.210773.112 · Cited by 1,231
Wang, K., Degerny, C., Xu, M., & Yang, X.-J. (2009) · Biochemistry and Cell Biology · doi:10.1139/o08-114 · Cited by 180 · cited 1×
“YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) are paralogs of WW domain-containing transcriptional coactivators, which share 60% similarity and activate many transcriptional factors important for the development of various tissues in mammals (7, 8).”
BackgroundSelf-citationEpithelial mesenchymal transition in drug resistance and metastasis of lung cancer
Nurwidya, F., Takahashi, F., Murakami, A., & Takahashi, K. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.151 · Cited by 177
Modularity in the Hippo signaling pathway
Sudol, M., & Harvey, K. F. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.010 · Cited by 149
Cited by
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
“M phase may promote neoplastic transformation via enhancing cell migration and invasion (Yang et al. 2013, 2015c), others suggest that anti-tubulin drugs require YAP phosphorylation by CDK1 to induce cancer cell death (Zhao et al. 2014).”
BackgroundThe Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387
“Moreover, cell-cycle kinase CDK1 inhibits YAP activity independent of the Hippo pathway by targeting sites on YAP upon antitubulin drug treatment (57).”
BackgroundYAP and TAZ: a nexus for Hippo signaling and beyond
Hansen, C. G., Moroishi, T., & Guan, K.-L. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.05.002 · Cited by 574
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
“Conversely, Cyclin-dependent kinase 1 (CDK1), sensitizes ovarian cancer cells to taxanes by phosphorylating LATS1/2 and YAP/TAZ [75,78,80,84,86,87].”
BackgroundHippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 420
Metadata
- Authors
- Zhao, Y., Khanal, P., Savage, P., She, Y.-M., Cyr, T. D., & Yang, X.
- Venue
- Cancer Research
- Published
- 2014-08-13
- Volume
- 74
- Issue
- 16
- Pages
- 4493-4503
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2119327914
- Cited by
- 95
- References
- 9
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-2712
- The paper
- Zhao, Y., Khanal, P., Savage, P., She, Y.-M., Cyr, T. D., & Yang, X. (2014). YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-2712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.